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Abstract: Polymer therapeutics offer potential benefits in the treatment of multidrug resistant 23 
(MDR) infections; affording targeted delivery of biologically active agents to the site of 24 
inflammation, potential decreases in systemic toxicity and the retention of antimicrobial 25 
activity at the target site. As a prototype model, these studies developed and characterized a 26 
library of dextrin-colistin conjugates (dextrin molecular weight: 7,500 - 48,000 g/mol) as a 27 
means of targeting the delivery of colistin. Optimum colistin release kinetics (following dextrin 28 
degradation by physiological concentrations of amylase (100 IU/L)) were observed in 29 
conjugates containing low molecular weight (~7,500 g/mol) dextrin with ~1 mol% 30 
succinoylation (~80% drug release within 48 h, compared to ~33% from sodium colistin 31 
methanesulfonate (CMS, Colomycin®)). These conjugates exhibited comparable antimicrobial 32 
activity to CMS in conventional MIC assays against a range of Gram-negative pathogens, but 33 
with significantly reduced in vitro toxicity towards kidney  (IC50 = CMS, 15.4 μg/mL; dextrin-34 
colistin, 63.9 μg/mL) and macrophage (IC50 = CMS, 111.3 μg/mL; dextrin-colistin, 303.9 35 
μg/mL) cells. In vivo dose-escalation studies in rats demonstrated improved pharmacokinetics 36 
of the conjugates, with prolonged plasma levels of colistin (t1/2 135-1271 min vs. 53 min) and 37 
decreased toxicity, compared to colistin sulfate. These studies highlight the potential utility of 38 
‘nanoantibiotic’ polymer therapeutics to aid the safe, effective and targeted delivery of colistin 39 
in the management of MDR infections.  40 
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Introduction 41 
The prevalence of infections by Gram-negative, multi-drug resistant organisms, including 42 
Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae, represents a world health 43 
problem and a significant clinical challenge in patients with chronic disease e.g. cystic fibrosis, in 44 
whom aminoglycoside and fluoroquinolone resistance is common1. Increasing resistance to currently-45 
available antibiotics has been mirrored by decreases in the design/development of new antibiotic 46 
entities1. To overcome these issues clinicians are employing antimicrobial agents (e.g. colistin and 47 
polymyxin B) which are effective against Gram-negative organisms, but have previously been 48 
restricted in clinical use due to the potential for asociated toxicity2. 49 
Polymer therapeutics are being increasingly investigated for the treatment of cancer, arthritis, 50 
viral infections3,4, and, more recently, tissue repair5-8. Indeed, two of the US top 10 selling drugs in 51 
2013 were polymer therapeutics (Neulasta® and Copaxone®)9. Whilst this technique has been 52 
extensively employed to reduce toxicity in the delivery of cytotoxic therapies in the treatment of 53 
malignancy3, surprisingly, little attention has been directed at their use in the treatment of bacterial 54 
infection. The conjugation of antibiotics to polymers offers the ability to improve biodistribution, 55 
enhance stability and reduce toxicity10,11. Polymer masked-unmasked protein therapy’ (PUMPT) is a 56 
technique, which employs conjugation of a biodegradable polymer to “mask” a protein or peptide’s 57 
activity in the circulation12. The circulating conjugate accumulates at the site of inflammation (or 58 
infection) due to the enhanced permeability and retention (EPR) effect11 and “locally-triggered” 59 
degradation of the polymer regenerates bioactivity. The application of PUMPT, to safely deliver 60 
antibiotic agents otherwise associated with toxicity or pharmacokinetic problems (e.g. colistin) may, 61 
therefore, offer not only the ability to design and deliver novel targeted therapies, but also to improve 62 
the safe treatment of patients with Gram-negative MDR infections.  63 
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In this study we sought to develop a novel, nanomedicine-based, delivery system to target the 64 
delivery of colistin. Colistin was chosen as a model antibiotic since it is an amphiphilic peptide 65 
antibiotic (Mw ~1,400 g/mol) which is highly active towards multi-resistant Gram-negative bacteria, 66 
but is not readily absorbed orally and the free drug is nephro- and neurotoxic13. Consequently, it is 67 
commonly administered intravenously as sodium colistin methanesulfonate (CMS), a less toxic pro-68 
drug, that is readily hydrolyzed to partially sulfomethylated derivatives and colistin in aqueous 69 
solution. This hydrolysis is however, neither controlled or triggered, and may even occur before patient 70 
administeration, which has resulted in fatality.  71 
We hypothesized that polymer conjugation would not only limit systemic toxicity, but passively 72 
target the protein to sites of infection/inflammation by the effect, which has been widely observed in 73 
cancer and, more recently, to a lesser extent, in inflammation11 (Figure 1). Dextrin was employed here 74 
as the model polymeric carrier as we have previously shown its suitability as a partner polymer in the 75 
context of PUMPT12, as it is rapidly degraded by -amylase14,15. We, and others, have shown how the 76 
conjugation can be tailored (employing dextrins of different molecular weights and degrees of 77 
succinoylation) to optimize the release and activity of the protein for particular clinical applications e.g. 78 
wound healing12,14,15.  79 
In the present work, we hypothesize that conjugation of dextrin to colistin will improve disease-80 
specific targeting and reduce the toxic effects of colistin, thus re-establishing its value in Gram-81 
negative infections and supporting the development of further polymer therapeutic nanoantibiotics. 82 
Here, the synthesis and characterization of a series of dextrin-colistin conjugates is reported and the 83 
ability of the conjugates to release colistin in the presence and absence of amylase at human 84 
physiological concentrations, their toxicity towards mammalian cells (erythrocytes, human kidney 85 
cells) and their in vitro antimicrobial activity is described. As dextrin conjugation is hypothesized to 86 
extend the serum half-life of colistin, an in vivo assessment of plasma drug concentration following a 87 
single bolus injection was performed in a dose-escalating study. 88 
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Materials and Methods 90 
Materials. Type 1 dextrin from corn (Mw ~ 48,500 g/mol) was from ML laboratories (Keele, 91 
UK). Type I dextrin from corn (Mw ~ 7,500 g/mol), dextrin from maize starch (Mw ~28,000 g/mol), 92 
colistin sulfate, -amylase from human saliva, N-hydroxysulfosuccinimide (sulfo-NHS), copper (II) 93 
sulfate pentahydrate 4% w/v solution, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide 94 
(MTT), bicinchoninic acid solution (BCA), ethanolamine, ninhydrin, hydrindantin, lithium acetate 95 
dihydrate, acetic acid and dimethyl sulfoxide (DMSO) were all from Sigma-Aldrich (Poole, UK). 96 
Dextrin from potato starch (Mw ~10,500 g/mol) was from Fluka (Gillingham, UK). 1-ethyl-3-(3-97 
dimethylaminopropyl carbodiimide hydrochloride) (EDC) was from Pierce (Rockford, USA). 98 
Disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, 4-99 
dimethylaminopyridine (DMAP) and sodium chloride were from Fisher Scientific (Loughborough, 100 
UK). Pullulan gel filtration standards (Mw = 11,800–210,000 g/mol) were from Polymer Laboratories 101 
(Church Stretton, UK). Lactate dehydrogenase (LDH)-cytotoxicity assay kit was from abcam 102 
(Cambridge, UK). MaxSignal® colistin ELISA test kit was from Bioo Scientific Corp. (Austin, USA). 103 
Unless otherwise stated, all chemicals were of analytical grade. All solvents were of general reagent 104 
grade (unless stated) and were from Fisher Scientific (Loughborough, UK).  105 
Cell culture. Mouse macrophage cells (RAW 264.7) and human kidney proximal tubule cells 106 
(HK-2) were from ATCC (Manassas, USA). Cells were screened and found to be free of mycoplasma 107 
contamination before use. Dulbecco's Modified Eagle's medium (DMEM) with GlutaMAXTM, fetal calf 108 
serum (FCS), keratinocyte serum-free medium (K-SFM) with L-glutamine, epidermal growth factor 109 
(EGF), bovine pituitary extract (BPE) and 0.05% w/v trypsin-0.53 mM EDTA were obtained from 110 
Invitrogen Life Technologies (Paisley, UK).  111 
Bacterial culture. The strains used for susceptibility testing include both culture collection 112 
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strains and clinical isolates (Table 1). Their known relevant genotypes and origin have been described 113 
by Khan et al.16. Bacterial colonies were grown on tryptone soya agar (TSA) and liquid cultures were 114 
suspended in tryptone soya broth (TSB) for overnight culture or Mueller-Hinton broth (MHB) for MIC 115 
determination (from Oxoid; Basingstoke, UK). 116 
Synthesis and purification of dextrin-colistin conjugates. First, succinoylated dextrins (1-60 117 
mol%) were synthesized, as previously described15 (Figure 2(a)). Briefly, with dextrin of molecular 118 
weight 7,500 g/mol, 5 mol% succinoylation was achieved as follows. Dextrin (1000 mg, 6.17 x 10-3 119 
mol) was dissolved in anhydrous DMF (10 mL) in a 50 mL round-bottomed flask. Succinic anhydride 120 
(61.7 mg, 6.17 x 10-4 mol) and DMAP (28.6 mg, 2.34 x 10-4 mol) were subsequently added, the 121 
reaction purged with nitrogen, sealed and left to stir at 50 oC for 18 h. Then, the reaction mixture was 122 
poured into vigorously stirring diethyl ether (250 mL) and stirred overnight. The ether was removed by 123 
filtration under vacuum and the residual solid was dissolved in minimal distilled water (dH2O), poured 124 
into a dialysis membrane (molecular weight cut-off 2,000 g/mol) and dialysed against 4 x 5 L dH2O. 125 
The resultant solution was freeze-dried to yield succinoylated dextrin. The degree of succinoylation 126 
was quantified by titration against a standard solution of NaOH (5 x 10-4 M) with bromophenol blue as 127 
indicator, and the product was further characterized by FT-IR (Avatar 360 ESP spectrometer with EZ 128 
OMNIC ESP 5.2 software; Thermo Nicolet, Loughborough, UK) to confirm identity and by gel 129 
permeation chromatography (GPC) (TSK G4000PWXL and G3000PWXL columns (Polymer 130 
Laboratories, Church Stretton, UK) in series, mobile phase PBS (pH 7.4), flow rate of 1 mL/min) to 131 
measure approximate molecular weight and polydispersity (compared to pullulan standards). Samples 132 
for GPC were prepared in PBS (3 mg/mL) and the eluate was monitored using a differential 133 
refractometer (Gilson 153). PL Caliber Instrument software, version 7.0.4, from Polymer Laboratories 134 
(Church Stretton, UK) was used for data analysis.  135 
Succinoylated dextrins (1-30 mol% succinoylation) were then conjugated to colistin (Figure 136 
2(b)). Briefly, for 10 mol% succinoylated dextrin, succinoylated dextrin (200 mg, 1.11 x 10-4 mol 137 
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COOH; 2.50 x 10-5 mol dextrin) was dissolved under stirring in dH2O (1 mL) in a 10 mL round-138 
bottomed flask. To this, EDC (21.3 mg, 1.11 x 10-4 mol) and sulfo-NHS (24.1 mg, 1.11 x 10-4 mol) 139 
were added, and the mixture was left stirring for 30 min. Subsequently, colistin (35 mg, 2.50 x 10-5 140 
mol) dissolved in dH2O (1 mL) was added, followed by NaOH (0.5 M) drop-wise to raise the pH to 141 
~8.0. The reaction mixture was left stirring for up to 18 h, typically for 2 h. The conjugate was then 142 
purified from the reaction mixture by fast protein liquid chromatography (FPLC) (ÄKTA FPLC; 143 
Amersham Pharmacia Biotech, UK) using a pre-packed Superdex 75 10/300 GL column with a UV 144 
detector and data analysis using Unicorn 4.0 software (Amersham Pharmacia Biotech, UK). Samples of 145 
the reaction mixture (0.5 mL) were injected into a 500 L loop using PBS (pH 7.4), pH 7.4 at 0.5 146 
mL/min as a mobile phase. Fractions (1 mL) were collected, desalted using Vivaspin tubes (5,000 147 
g/mol cut-off) and assayed for protein content (BCA assay) before pooling fractions containing 148 
conjugate (typically fractions 6-13). The final conjugate was lyophilised and stored at -20 oC. 149 
Characterization of dextrin-colistin conjugates. Dextrin-colistin was characterized by FPLC 150 
and GPC to assess purity and estimate molecular weight, and the total protein content of the conjugate 151 
was determined by the BCA assay using colistin standards.  152 
The FPLC system described above for purification was used again for final conjugate 153 
characterization. Samples (200 L) were dissolved in PBS (pH 7.4) and injected into a 100 L loop at 154 
0.5 mL/min. The molecular weight was estimated using GPC relative to pullulan standards. 155 
Ninhydrin assay. Prior to conjugation of polymer to protein, a ninhydrin assay was used to 156 
confirm the number of available amine groups in colistin for conjugation and how many amine groups 157 
were subsequently used for binding to dextrin. First, a 4 M lithium acetate buffer solution was prepared 158 
by dissolving lithium acetate dihydrate (40.81 g) in 60 mL dH2O. Sufficient acetic acid (glacial) was 159 
added until pH 5.2 was reached. The volume was made up to a final volume of 100 mL with dH2O. 160 
Next, ninhydrin (0.2 g) and hydrindantin (0.03 g) were dissolved in 7.5 mL DMSO and 2.5 mL lithium 161 
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acetate buffer. Buffered ninhydrin reagent (86 L) was added to an equal quantity of sample/ standard 162 
solution (1.5 mL eppendorf) and heated in a water bath at 100 oC for 15 min. The mixture was 163 
subsequently cooled to room temperature and 130 L of 50% v/v ethanol was added. The solution was 164 
mixed before adding 200 L of the final solution into wells of a 96-well plate. Spectrophotometric 165 
analysis was performed at 570 nm. Calibration of the assay was achieved using ethanolamine (0-0.1158 166 
mM). 167 
Degradation of dextrin, succinoylated dextrin and dextrin-colistin conjugates by amylase. 168 
To compare the rate of amylase degradation of dextrin, succinoylated dextrin and dextrin-colistin 169 
conjugates, solutions (3 mg/mL in PBS, pH 7.4) of each sample was prepared containing amylase (100 170 
IU/L in PBS) and incubated at 37 oC for up to 48 h. At various time points, samples (300 L) were 171 
taken, immediately snap-frozen in liquid nitrogen to stop the reaction and stored at –20 ºC until 172 
analysis by GPC and FPLC (conjugates only). Prior to analysis, samples were placed in a water bath 173 
(100 oC) for 5 min to denature the enzyme activity of the amylase and stop polymer degradation. The 174 
supernatant was then analyzed by GPC to determine the change in molecular weight over time and by 175 
FPLC to determine the change in free colistin over time.  176 
In vitro toxicity assay: MTT assay. An MTT assay was used to assess cell viability in a mouse 177 
macrophage (RAW 264.7) cell line (24 h incubation) and a human kidney (HK-2) cell line (72 h 178 
incubation). RAW 264.7 cells were seeded into sterile, 96-well microtiter plates (2 x 105 cells/mL) in 179 
0.1 mL/well of media (DMEM) containing heat-inactivated FCS (1% v/v) and HK-2 cells were seeded 180 
into sterile 96-well microtiter plates (1 x 105 cells/mL) in 0.1 mL/well of media (K-SFM) containing L-181 
glutamine, EGF and BPE. They were allowed to adhere for 24 h. The medium was then removed and 182 
test compounds (0.2 m filter-sterilized) were added to the cells. To study the effect of colistin sulfate, 183 
CMS and dextrin-colistin conjugate (7,500 g/mol, 1.1 mol% succinoylation) on cell viability, complete 184 
media was supplemented with a range of concentrations of each. To study the effect of ‘unmasked’ 185 
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dextrin-colistin on cell viability, complete media was supplemented with a range of concentrations of 186 
conjugate and amylase (100 IU/L). After a further 67 h incubation, MTT (20 L of a 5 mg/mL solution 187 
in PBS) was added to each well and the cells were incubated for a further 5 h. The medium was then 188 
removed and the precipitated formazan crystals solubilized by addition of optical grade DMSO (100 189 
L) over 30 min. Absorbance was measured at 540 nm using a microtiter plate reader. Cell viability 190 
was expressed as a percentage of the viability of untreated control cells. The IC50 values were 191 
expressed as mean ± SEM (n=18). 192 
In vitro toxicity assay: LDH assay. The LDH assay was used to assess cell membrane damage 193 
(24 h incubation) in a HK-2 cell line. Cells were seeded into sterile 96-well microtiter plates (1 x 105 194 
cells/ mL) in 0.1 mL/well of media (K-SFM) containing L-glutamine, EGF and BPE. They were 195 
allowed to adhere for 24 h. The medium was then removed and test compounds (0.2 m filter-196 
sterilized) were added to the cells. To study the effect of colistin sulfate, CMS and dextrin-colistin 197 
conjugate on cell membrane integrity, complete media was supplemented with a range of 198 
concentrations of each. To study the effect of ‘unmasked’ dextrin-colistin on cell viability, complete 199 
media was supplemented with a range of concentrations of conjugate and amylase (100 IU/L). After 24 200 
h, microtiter plates were centrifuged (600 g, 10 min), the supernatant was transferred to a clean 96-well 201 
plate and stored at -20 oC until determination of LDH content. LDH content in the cell supernatant was 202 
determined using a commercial LDH-cytotoxicity assay kit following the manufacturer’s protocol. 203 
Absorbance was measured at 450 nm using a microtiter plate reader. The absorbance values were 204 
expressed as mean ± SEM (n=6). 205 
Measurement of antimicrobial activity. Antimicrobial activity was measured using broth 206 
micro-dilution in a standard MIC assay17. Test organisms were suspended in Mueller Hinton cation-207 
adjusted broth (100 L, 1 - 5 x 104 CFU/mL) and incubated in 96-well microtiter plates in serial two-208 
fold dilutions of the test compounds.  209 
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The antimicrobial activity of dextrin-colistin conjugates was similarly determined following 210 
incubation (3 mg/mL colistin equiv.) with amylase (100 IU/L for up to 48 h at 37 C in PBS buffer (pH 211 
8.2)).  212 
In vivo dose escalating studies. Sprague-Dawley rats (390-470 g) (Charles River (UK) 213 
Limited) with a jugular vein cannulation were housed in an animal care facility and acclimatised for 1 214 
week prior to experimentation. During the on-study period, rats were housed individually in a 215 
metabolism cage with food and water ad libitum. 216 
On the day of the experiment, colistin sulfate, dextrin-colistin conjugate (1.4 mol% 217 
succinoylated 7,500 g/mol dextrin) and dextrin-colistin conjugate (7.2 mol% succinoylated 7,500 g/mol 218 
dextrin) were dissolved in 0.9% w/v sterile saline (0.1 mg/mL colistin equiv.), filtered (0.22 m) and 219 
injected via the tail vein as a bolus to 2 rats per test item (0.1 mg/kg colistin equiv.). Following 220 
administration, blood was collected (5 and 30 min, 1, 4, 8 and 24 h post-dose). Blood samples were 221 
placed into tubes containing lithium heparin and centrifuged (3000 rpm, for 10 min at 4 oC) 222 
immediately, before storing the resulting plasma samples at -20 oC prior to assay.  The concentration of 223 
“total” colistin in plasma was assessed using a commercial colistin ELISA test kit, according to the 224 
manufacturer’s instructions. 225 
Pharmacokinetic Analysis. Non-compartmental analysis of the pharmacokinetics of colistin 226 
sulphate and dextrin-colistin conjugates was performed using GraphPad Prism, version 6.0d for 227 
Macintosh, 2014. The following pharmacokinetic parameters were calculated: peak plasma colistin 228 
concentration after administration (Cmax), time to reach (tmax), plasma half-life (t1/2), area under the 229 
concentration-time curve to 24 h (AUC0-24 h), volume of distribution (Vd) and total body clearance (CL). 230 
Plasma half-life was calculated following linear regression analysis of log-transformed plasma 231 
concentration–time points. The AUC0–24 h of colistin was calculated with the presumption of the initial 232 
concentration being zero.  233 
Statistical Analysis. Data are expressed as mean  the error, calculated as either standard 234 
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deviation (SD) where n = 3, or standard error of the mean (SEM) where n > 3. Statistical significance 235 
was set at p < 0.05 (indicated by *). Evaluation of significance was achieved using a one-way analysis 236 
of variance (ANOVA) followed by Bonferroni post hoc tests that correct for multiple comparisons. All 237 
statistical calculations were performed using GraphPad Prism, version 6.0d for Macintosh, 2014. 238 
 239 
Results 240 
Synthesis and characterization of dextrin-colistin conjugates. The characteristics of the 241 
library of succinoylated dextrins synthesized are summarized in Table 1. Succinoylated dextrin 242 
intermediates were synthesized having a degree of modification of 1-29 mol% and showed increased 243 
FT-IR signal strength of the ester peak (~1,720 cm-1) relative to degree of modification (Figure 3(a) 244 
and Figure SI 1(a, c, e)). GPC using pullulan standards suggested an increase in dextrin molecular 245 
weight following succinoylation with little change in polydispersity.  246 
Using theses succinoylated dextrin intermediates, a series of dextrin-colistin conjugates were 247 
prepared (Table 1). Typical FPLC elution profiles of the purified conjugates and free colistin are shown 248 
(Figure 3(b)), with the conjugate typically eluting in the void volume of the column, enabling the 249 
separation of free and bound colistin. The protein content was 3-23% w/w. FPLC analysis confirmed 250 
the presence of a high molecular weight conjugate, however, the free colistin content was always < 4%. 251 
The ninhydrin assay indicated that colistin has 4.8 NH2 groups per molecule and that dextrin typically 252 
bound to ~3 of these groups in dextrin-colistin conjugates. 253 
Degradation of dextrin and dextrin-colistin conjugate by amylase. GPC analysis of dextrin 254 
degradation by amylase revealed a decrease in molecular weight with time (Figure 4(a) and Figure SI 255 
1(b,d,f)). While dextrin degraded rapidly (t1/2<30 min) in the presence of amylase, chemical 256 
modification by succinoylation slowed the rate of degradation (t1/2 ≥ 4 h).  257 
When degraded dextrin-colistin conjugates were analyzed by FPLC, a peak corresponding to 258 
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free colistin appeared (~16 mL), which increased in intensity with time (Figure 4(c) and Figure SI 2). 259 
In parallel, the peak corresponding to dextrin-colistin conjugate (~7.5 mL) decreased and GPC analysis 260 
revealed a reduction in conjugate molecular weight over the incubation timecourse (Figure 4(b)). This 261 
corresponds to an increasing concentration of free colistin in parallel to reducing concentrations of 262 
dextrin-colistin conjugate; indicative of release of colistin from the conjugate due to amylase 263 
degradation of dextrin. In these experiments, dextrin-colistin conjugates containing low molecular 264 
weight dextrin (7,500 g/mol) with a low level of polymer modification (1.1 mol%) released the most 265 
free colistin (~80%) after 48 h incubation (Table SI 1). Amylase-triggered dextrin-colistin conjugates 266 
synthesized using low molecular weight (7,500 g/mol) dextrin released more than twice as much free 267 
colistin within 48 h than the commercially available CMS (Figure 4(d)). 268 
Stability of dextrin-colistin and CMS in vitro. Dextrin-colistin conjugates (7,500 g/mol 269 
conjugates at 1.1, 2.5, 4.7 and 8.3 mol%) were stable in water and PBS at 4 oC (Figure 5, Table SI 1). 270 
After 48 h, the percentage of liberated colistin was typically <5%. Dextrin-colistin conjugates were less 271 
stable in water at 37oC in the absence of amylase, and increased colistin was evident in PBS at 37oC in 272 
the absence of amylase. Release of colistin by hydrolysis was also greatest for conjugates containing 273 
low degrees of succinoylation. CMS was less stable in PBS than water, releasing 33.0% free colistin 274 
after 48 h in PBS at 37oC. After incubation of CMS in PBS or water at 4oC for 48 h, more free colistin 275 
was detected than for any of the dextrin-colistin conjugates. 276 
In vitro toxicity assay. The concentration-dependent cytotoxicity of colistin sulfate, CMS and 277 
dextrin-colistin conjugates (with and without amylase) is shown in Figure 6. The dextrin-colistin 278 
conjugate caused less metabolic changes and membrane damage than free colistin and CMS in RAW 279 
264.7 and HK-2 cells. Cell viability, measured by MTT assay, was greatest in HK-2 (kidney) cells 280 
(IC50 = 11.0 ± 1.0 g/mL (colistin sulfate) > 15.4 ± 1.0 g/mL (CMS) > 35.5 ± 1.3 g/mL (dextrin-281 
colistin with amylase) > 63.9 ± 1.6 g/mL (dextrin-colistin)), compared to RAW 264.7 (macrophage) 282 
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cells (IC50 = 111.3 ± 1.1 g/mL (CMS) > 180.5 ± 1.3 g/mL (dextrin-colistin with amylase) > 187.4 ± 283 
1.1 g/mL (colistin sulfate) > 303.9 ± 1.4 g/mL (dextrin-colistin)) (Figure 6(a,b)). Similarly, the LDH 284 
assay in HK-2 cells demonstrated that dextrin-colistin conjugate caused significantly less (~50%) 285 
membrane damage than colistin sulfate or CMS (Figure 6(c)), however, amylase unmasking of dextrin-286 
colistin conjugate restored the membrane permeabilization activity of colistin. Likewise, dextrin-287 
colistin conjugates induced significantly less erythrocyte lysis after a 24 h incubation than colistin 288 
sulfate or CMS, even in the presence of amylase (Figure 6(d)).  289 
 Measurement of antimicrobial activity. Conjugation of dextrin masked the antimicrobial 290 
activity of colistin in a panel of Gram-negative bacteria to some extent, typically increasing the MIC to 291 
2-fold that of CMS. Pre-incubation with amylase (at physiological concentrations) generally caused a 292 
1-fold reduction in MIC value, compared to untreated conjugate (Tables 2, SI 2). Antimicrobial activity 293 
was greatest for conjugates containing low molecular weight dextrin (7,500 g/mol) with a low degree 294 
of succinoylation (1.1 mol%).  295 
In vivo pharmacokinetics. Figure 7 shows the mean concentrations of colistin in plasma as a 296 
function of time in 2 rats after an IV dose of 0.1 mg/kg colistin sulfate or dextrin-colistin conjugates. In 297 
all cases, there was a short distribution phase (5-60 min) followed by an elimination phase. After 8 h, 298 
the concentration of colistin sulfate was below the limit of quantification, but for both conjugates, drug 299 
was detectable in the plasma 48 h post-dose. Colistin sulfate had a significantly shorter half-life than 300 
the dextrin-colistin conjugates (53.2 min vs. 135.3 min (1.1 mol%) and 1,270.9 min (7.2 mol%)) (Table 301 
3). 302 
 303 
Discussion 304 
While previous applications of PUMPT, in cancer and wound repair5,18, require prolonged 305 
release of the bioactive protein over several days, acute bacterial infections need much more rapid and 306 
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complete release of the antibiotic at sites of infection. Here we have optimized the release of colistin by 307 
varying the degree of dextrin functionalization. It has previously been shown that dextrin’s degradation 308 
rate, and consequent drug release, can be extended by increasing its molecular weight and degree of 309 
succinoylation12. In these studies, dextrin-colistin conjugates were synthesized using dextrins with 310 
molecular weights between 7,500 and 48,500 g/mol and 1-29 mol% succinoylation. Typically, dextrin-311 
colistin conjugates contained 1-2 dextrin chains per colistin molecule, bound via ~3 primary amine 312 
groups. Dextrin degradation by amylase breaks the glycosidic bonds within the polymer chain, leaving 313 
oligosaccharides and/or maltose linked to colistin. These cationic amine groups play an important role 314 
in the interaction of colistin with bacterial lipopolysaccharides, as well as permeabilization of the 315 
kidney’s proximal tubule, so the number of binding sites was optimized to sufficiently ‘mask’ colistin 316 
during transit but allow sufficient antimicrobial activity to be regenerated at the target site. 317 
Couet et al.19 recently reported that only 30% of the CMS dose administered intravenously to 318 
healthy volunteers was converted into colistin after 24 h. Here, we demonstrated, using FPLC, that in 319 
vitro hydrolysis of CMS in PBS at 37 oC released just 23.6% free colistin after 24 h. In contrast, 320 
amylase-triggered release of colistin from dextrin-colistin conjugates released up to 80% free drug in 321 
the same period. While amylase triggered significant release of free colistin from conjugates, stability 322 
experiments showed that drug may also be released at a slower rate in the absence of amylase. This is 323 
important as some patients, such as those with cystic fibrosis, display reduced physiological levels of 324 
amylase20, and ‘enzyme-free’ liberation of drug may be an advantage in these patients.  In all cases, 325 
however, the release of free colistin from dextrin-colistin conjugates was less than from amylase-326 
activated conjugates. While in vivo liberation of colistin from dextrin-colistin conjugates is important 327 
for antibacterial activity, release of drug during storage may be harmful. Storage of the dextrin-colistin 328 
conjugates in solution at 4oC resulted in minimal (≤5.3% after 48 h) colistin release, however, up to 329 
13.2% colistin was liberated from CMS under the same conditions.  330 
Colistin exerts its bactericidal activity by permeabilizing bacterial membranes21,22. However, 331 
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since this mechanism is only partially selective, polymyxins can also increase the permeability of 332 
mammalian cells- leading to an increased influx of cations, anions, and water, which eventually result 333 
in cell swelling and lysis23,24. Permeabilization of renal proximal tubule cells has been attributed to 334 
colistin’s dose-dependent nephrotoxicity, affecting up to 36% of patients receiving intravenous CMS25. 335 
Biocompatibility of dextrin-colistin conjugates is essential for safe systemic administration. HK-2 cells 336 
were chosen for these preliminary in vitro toxicity studies since they are derived from the proximal 337 
cells of human kidneys and are known to retain the functional characteristics of proximal tubular 338 
epithelium26. The MTT and LDH assays demonstrated that dextrin conjugation significantly reduced 339 
the cytotoxicity of colistin. Since colistin is only weakly cytotoxic (compared to an anti-cancer agent), 340 
and toxicity normally ensues from long-term use, treatment incubation times for the toxicity assays 341 
were chosen to replicate the prolonged exposure observed from the conjugates due to extended plasma 342 
half-life observed in the in vivo studies. Given that hemocompatibility would be critical to ensure safe 343 
systemic administration of dextrin-colistin conjugates following IV injection, the finding that the 344 
concentration-dependent erythrocyte toxicity exhibited by colistin was effectively inhibited by dextrin 345 
conjugation, but only partially restored after amylase unmasking, was also encouraging. In these 346 
experiments, dextrin conjugation via colistin’s cationic amine groups, and the inability of amylase 347 
degradation to restore these positively charged groups, could explain the reduced toxicity of dextrin-348 
colistin conjugates in comparison to colistin and CMS and support the ‘masking’ effect of polymer 349 
conjugation. Previous attempts to reduce the toxicity of polymyxin antibiotics, by eliminating two of 350 
the five cationic groups, have been described by Vaara et al, resulting in a 6-7-fold lower affinity for 351 
the brush border membrane of the renal cortex27. 352 
Having confirmed that dextrin conjugation could mask colistin’s cytotoxicity, it was important 353 
to confirm that conjugates retained antimicrobial activity prior to future clinical testing. Drug resistance 354 
often occurs when bacteria are exposed to sub-optimal concentrations of antibiotic, while high doses 355 
can cause unpleasant or harmful side effects. Masking of antibiotic activity in transit followed by 356 
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efficient reinstatement of antibiotic activity after passive localisation at sites of infection/ inflammation 357 
by the EPR effect, provides an ideal means of optimising drug dosing to reduce the emergence of 358 
resistance. The Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints for 359 
colistin have been identified in Acinetobacter baumannii (susceptible, ≤2 mg/L; resistant, ≥4 mg/L) 360 
and Pseudomonas aeruginosa (susceptible, ≤2 mg/L; intermediate, 4 mg/L; resistant, ≥8 mg/L)28, while 361 
the general MIC breakpoints for CMS susceptibility are typically higher (susceptible, ≤4 mg/L; 362 
resistant, ≥8 mg/L)29, Despite their higher in vitro cytotoxicity, colistin sulfate and CMS were very 363 
active against Gram-negative bacteria (with MIC values as low as 0.016 mg/L and 0.25 mg/L, 364 
respectively) (Table 2). As expected, dextrin conjugation reduced the antimicrobial activity of colistin, 365 
with dextrins of higher molecular weight and degrees of succinoylation causing an almost quantitative 366 
decrease in activity. Dextrin-colistin conjugates were not always below the susceptibility breakpoints, 367 
even after amylase unmasking with equivalent concentrations of amylase as that found in human 368 
serum. However, since dextrin-colistin conjugates are hypothesized to accumulate in areas of 369 
inflammation and infection by the EPR effect11, serum concentration will not predict the drug 370 
concentration at disease sites and pharmacokinetic studies will be important to characterize the 371 
distribution and local concentration of the conjugates.  This will represent an important future series of 372 
experiments in pre-clinical studies.  373 
The pharmacokinetics of a single IV bolus dose of two “prototype” conjugates with contrasting 374 
degrees of succinoylation (1.4 and 7.2 mol%) was tested in comparison to colistin sulfate, to determine 375 
if conjugation increased the plasma half-life of colistin, and to help identify a suitable dosing interval 376 
for subsequent repeated-dose studies. These studies employed a commercial colistin ELISA test kit 377 
since high-performance liquid chromatography (HPLC), the standard method for colistin detection in 378 
plasma and urine30-33, was not possible as dextrin conjugation inhibits colistin binding to the HPLC 379 
column (data not shown). In accordance with our hypothesis, preliminary experiments showed that, 380 
after IV administration, the blood clearance of dextrin-colistin conjugates was markedly inhibited by 381 
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conjugation. Similarly, conjugation of dextrin (6,600 g/mol) to zidovudine also extended the plasma 382 
half-life from 1.3 to 19.3 h and an increase in the area under the plasma concentration-time curve34. 383 
The effect of degree of dextrin succinoylation on in vivo pharmacokinetics has not previously been 384 
reported, however, as hypothesized, increasing the degree of modification led to extended plasma half-385 
life of colistin. Given that serum amylase concentration in rats is in excess of 20 times higher than in 386 
human serum35,36, we predict that unmasking of the conjugate in humans would be slower, thereby 387 
increasing plasma retention further. Rats in these studies had a plasma amylase concentration of 3,068 388 
 119 IU/L (measured by Phadebas® assay), compared to the normal human plasma amylase range of 389 
40-125 IU/L. Interestingly, whilst this study was not designed to measure toxicity, the administration of 390 
0.5 mg/kg colistin sulfate, induced signs of systemic toxicity which prevented sampling until 2 h post-391 
dose, which was not evident at equivalent concentrations of the dextrin-colistin conjugates. 392 
These studies demonstrate the clear potential of bioresponsive polymer therapeutics-based 393 
“nanoantibiotics”, in which colistin is conjugated to dextrin, a clinically approved biodegradable 394 
polymer. Having established the optimum composition of dextrin-colistin conjugates which show 395 
comparable antimicrobial activity to commercially available CMS, but with reduced toxicity, ongoing 396 
work is determining in vivo distribution and clinical effectiveness. 397 
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Table 1 Characteristics of succinoylated dextrins and dextrin-colistin conjugates. 
 Dextrins Dextrin-colistin conjugates 
Compound Mwa  
(g/mol) 
(Mw/Mn) 
Succinoylation 
(mol%) 
Mwa  
(g/mol) 
(Mw/Mn) 
Protein 
content 
(% w/w) 
Molar ratio 
(dextrin:colistin) 
Conjugated 
NH2 per 
moleculeb 
Free 
protein 
(%) 
Colistin 1,408       
Dextrin 7,500 (1.8)       
Succ. dextrin (7,500 g/mol) 8,500 (1.9) 1.1 9,000 (1.5) 10.1 1.6:1 3.3 3.6 
Succ. dextrin (7,500 g/mol) 9,000 (1.9) 2.5 14,500 (1.5) 17.0 0.9:1 3.2 3.7 
Succ. dextrin (7,500 g/mol) 9,500 (2.0) 4.7 15,500 (1.7) 22.2 0.6:1 3.0 3.0 
Succ. dextrin (7,500 g/mol) 12,000 (1.8) 8.3 22,000 (1.6) 21.6 0.6:1 3.5 0.7 
Dextrin 10,500 (2.6)       
Succ. dextrin (10,500 g/mol) 13,500 (2.0) 2.2 35,000 (2.7) 10.6 0.8:1 1.4 2.8 
Succ. dextrin (10,500 g/mol) 17,500 (2.2) 4.3 165,000 (4.3) 11.5 0.7:1 1.6 2.4 
Succ. dextrin (10,500 g/mol) 17,500 (2.0) 7.0 180,000 (6.4) 14.5 0.4:1 1.4 2.7 
Dextrin 28,000 (2.6)       
Succ. dextrin (28,000 g/mol) 28,500 (1.9) 2.0 95,000 (4.3) 3.3 
 
1.4:1 2.2 1.3 
Succ. dextrin (28,000 g/mol) 39,000 (2.0) 3.4 140,000 (3.8) 3.0 1.5:1 1.4 1.2 
Succ. dextrin (28,000 g/mol) 45,000 (1.9) 6.1 270,000 (5.5) 6.6 0.7:1 1.0 0.8 
Dextrin 48,500 (2.2)       
Succ. dextrin (48,500 g/mol) 98,000 (1.9) 17.4 55,000 (1.8) 5.1 1:1 1.2 0.1 
Succ. dextrin (48,500 g/mol) 97,000 (1.7) 28.6 66,500 (1.7) 7.3 0.7:1 1.3 0.1 
a Mw was estimated by GPC using pullulan standards. 
b usually 4.81 NH2 per free colistin. 
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Table 2 Antimicrobial activity of colistin sulfate, CMS and dextrin-colistin conjugates* (containing 1.1 mol% succinoylated dextrin with and 
without amylase pre-exposure), measured by MIC assay. Data is expressed as mode (n=3). *MIC value represents equivalent colistin 
concentration of conjugates. 
 g/L) 
Isolate 
Colistin sulfate CMS Conjugate at indicated amylase pre-incubation (h) 
  0 3 6 24 
V4 A. baumannii MDR ACB 0.125 4 8 8  8 8 
V9 A. baumannii 0.25 4 16 16 16 8 
V19 A. baumannii 7789 0.25 2 8 16 8 16 
V20 A. lwoffi 8065 0.063 1 8 4 4 4 
V22 A. lwoffi 6056 0.125 2 16 8 8 8 
V5 E. coli AIM-1  0.016 0.25 1 0.5 0.5 0.125 
V11 E. coli 5702 0.5 1 8 4 8 2 
V24 E. coli 7273 0.25 2 16 32 16 8 
V12 K. pneumoniae 5725 0.5 1 4 4 4 2 
V6 K. pneumoniae IR25 0.5 2 8 8 8 8 
V8 K. pneumoniae K3 0.5 2 8 16 16 8 
V3 K. pneumoniae KP05 506 0.25 2 4 16 16 16 
V13 P. aeruginosa PA01 0.25 1 64 64 128 64 
V1 P. aeruginosa R22 0.5 0.5 128 128 128 128 
V2 P. aeruginosa MDR 301 0.5 1 512 512 512 512 
V7 P. stuartii IR57 0.25 1 4 16 8 8 
24 
Table 3 Mean estimates of pharmacokinetic parameters for colistin sulfate or dextrin-
colistin conjugates in rats (n = 2). 
Pharmacokinetic 
parameter 
Colistin 
sulfate 
Dextrin-colistin 
(1.4 mol%) 
Dextrin-colistin 
(7.2 mol%) 
Cmax (ng/mL) 96.1 106.7 101.6 
tmax (min) 5 30 60 
t1/2 (min) 53.2 135.3 1270.9 
AUC0-24 h  (mg.min/mL) 0.0082 0.0342 0.0913 
Vd (mL/kg) 669.7 676.4 925.7 
CL (mL/min/kg) 13.4 2.8 1.1 
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Legends to Figures 
Figure 1 Schematic showing the proposed mechanism of action of dextrin-
colistin conjugates.  
 
Figure 2 Synthesis of (a) succinoylated dextrin; and (b) dextrin-colistin 
conjugates.  
 
Figure 3 Characterization of succinoylated dextrin intermediates and dextrin-
colistin conjugates. (a) FT-IR spectra showing amplification of peak 
intensity at 1720 cm−1 with increasing incorporation of carboxyl 
groups; and (b) FPLC chromatogram of dextrin-colistin conjugates 
containing dextrins (7,500 g/mol) with different degrees of 
succinoylation (V0 = void volume (7.7 mL)). 
 
Figure 4 Characterization of the degradation of dextrin, succinoylated dextrin 
and dextrin-colistin conjugates (3 mg/mL) in the presence of amylase 
(100 IU/L in PBS at 37 oC). Panels (a) and (b) show the change in 
relative molecular weight in the presence of amylase by GPC of (a) 
native dextrin (7,500 g/mol) and its succinoylated intermediates; and 
(b) dextrin-colistin conjugates containing dextrin (7,500 g/mol) with 
different degrees of succinoylation. Panel (c) shows a typical elution 
profile of dextrin-colistin conjugate (containing 7,500 g/mol dextrin, 
4.7 mol% succinoylation) from a Superdex 75 FPLC column, following 
incubation with amylase (V0 = void volume (7.7 mL)), and panel (d) 
shows the release of colistin from dextrin-colistin conjugates 
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(containing 7,500 g/mol dextrin; 3 mg/mL) in the presence of amylase 
(100 IU/L in PBS) and CMS (3 mg/mL) in PBS at 37 oC (measured by 
FPLC). Data is expressed as the percentage of total colistin. (n=1). 
Where  = dextrin or dextrin-colistin conjugate;  = 1.1 mol% dextrin 
or dextrin-colistin conjugate;  = 2.5 mol% dextrin or dextrin-colistin 
conjugate;  = 4.7 mol% dextrin or dextrin-colistin conjugate;  = 8.3 
mol% dextrin or dextrin-colistin conjugate;  = 21.3 mol% dextrin or 
dextrin-colistin conjugate and  = CMS. 
 
Figure 5 Stability of dextrin-colistin conjugates (containing 7,500 g/mol dextrin; 
3 mg/mL) in dH2O and PBS at pH 7.4 (37 
oC) in the absence of 
amylase (measured by FPLC), and in comparison with amylase-treated 
conjugates. Data is expressed as the percentage of total colistin. Panels 
show conjugates containing (a) 1.1 mol% succinoylation, (b) 2.5 mol% 
succinoylation, (c) 4.7 mol% succinoylation, and (d) 8.3 mol% 
succinoylation. Where  = dextrin-colistin conjugate with amylase 
(100 IU/L) in PBS at 37 oC;  = dextrin-colistin conjugate in PBS at 
37 oC;  = dextrin-colistin conjugate in PBS at 4 oC;  = dextrin-
colistin conjugate in dH2O at 37 
oC and  = dextrin-colistin conjugate 
in dH2O at 4 
oC. 
 
Figure 6 In vitro cytotoxicity of colistin sulfate, CMS and dextrin-colistin 
conjugates. Panels (a) and (b) show cell viability by MTT assay of 
RAW 264.7 (24 h incubation) and HK-2 (72 h incubation) cells, 
respectively, following incubation with colistin sulfate, CMS or 
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dextrin-colistin conjugate with and without amylase (100 IU/L) at 37 
oC. Data is expressed as mean % untreated control ± SEM, n=18. Panel 
(c) shows membrane integrity by LDH assay of HK-2 cells incubated 
for 24 h with colistin, CMS or dextrin-colistin with and without 
amylase (100 IU/L) at 37 oC.  Data is expressed as mean ± SEM, n=6. 
Panel (d) shows hemolysis of rat erythrocytes following incubation for 
24 h with colistin, CMS or dextrin-colistin conjugate with and without 
amylase (100 IU/L) at 37 oC. Data is expressed as mean % triton X-100 
control ± SEM, n=18. Where  = colistin sulfate;  = CMS;  = 
dextrin-colistin conjugate and  = dextrin-colistin conjugate with 
amylase. * indicates significance (p<0.05) compared to colistin sulfate; 
** indicates significance (p<0.01) compared to colistin sulfate; *** 
indicates significance (p<0.001) compared to colistin sulfate. 
 
Figure 7 Mean plasma concentration of colistin following an IV dose of colistin 
sulfate, dextrin-colistin conjugate (1.4 mol%) and dextrin-colistin 
conjugate (7.2 mol%) (0.1 mg/kg). Data is expressed as colistin 
concentration ± S.D. (n=2). Concentrations of colistin following 
administration of colistin sulfate were not quantifiable beyond 4 h. 
Where  = colistin sulfate;  = dextrin-colistin conjugate (with 1.4 
mol% succinoylation) and  = dextrin-colistin conjugate (with 7.2 
mol% succinoylation). * indicates significance (p<0.05) compared to 
colistin sulfate; ** indicates significance (p<0.01) compared to colistin 
sulfate; *** indicates significance (p<0.001) compared to colistin 
sulfate. 
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